- Recruiting
NCT04614636: Phase 1 - FT538 in Subjects With Advanced Hematologic Malignancies
Updated: May 25, 2022
FT538
induced pluripotent stem cell-derived CD16/IL-15RF-expressing CD38-eliminated natural killer cells FT538

NCT04614636: Phase 1 - FT538 in Subjects With Advanced Hematologic Malignancies
This is a Phase I dose-finding study of FT538 as monotherapy in acute myeloid leukemia (AML) and in combination with monoclonal antibodies in multiple myeloma (MM). The study will consist of a dose-escalation stage and an expansion stage where participants will be enrolled into indication-specific cohorts.
Sponsor
ClinicalTrials.gov Identifier: NCT04614636
Official Title: A Phase I, Open-Label, Multicenter Study of FT538 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory Multiple Myeloma
First Posted : November 4, 2020
Click here for details on ClinicalTrials.gov
iPSC-derived CD16/IL-15RF-expressing CD38-eliminated NK Cells FT538 (Code C176623)
FT 538
FT-538
FT538
induced pluripotent stem cell-derived CD16/IL-15RF-expressing CD38-eliminated natural killer cells FT538
Drug: FT538
Drug: Cyclophosphamid
Drug: Fludarabine
Drug: Daratumumab
Drug: Elotuzumab
- Multiple locations
- New York: Memorial Sloan-Kettering Cancer Center New York
- Tennessee: Sarah Cannon Research Institute Nashville
- Missouri: Washington University School of Medicine Saint Louis
- Texas: The University of Texas MD Anderson Cancer Center Houston
Locations
United States, Colorado
United States, Minnesota
United States, Missouri
United States, New Jersey
United States, New York
United States, Tennessee
United States, Texas